Title page
Word count: 2762

Title: Chemosensory dysfunctions induced by COVID-19 can persist

up to 7 months: A study of over 700 healthcare workers

Authors: Nicholas **Bussière**[1]; Jie **Mei**[1], PhD; Cindy **Lévesque-Boissonneault**[1], MSc; Mathieu

Blais[2,3], PhD; Sara **Carazo**[4], MD, PhD; Francois **Gros-Louis**[2,3], PhD; Gaston **De Serres**[4], MD,

PhD; Nicolas **Dupré**[5,6], MD, MSc, FRCP FAAN; Johannes **Frasnelli**[1], MD

[1] Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

[2] Axe Médecine régénératrice, CHU de Québec–Université Laval, Québec City, QC, Canada

[3] Faculty of Medicine, Department of Surgery, Université Laval, Québec City, QC, Canada

[4] Institut National de Santé Publique du Québec, Québec City, QC, Canada

[5] Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada

[6] Axe Neurosciences, CHU de Québec–Université Laval, Québec City, QC, Canada

Correspondence to be sent to :

Johannes Frasnelli MD,

Université du Québec à Trois-Rivières,

3351, boul. des Forges, C.P. 500,

Trois-Rivières, QC G9A 5H7 Canada

Email: johannes.a.frasnelli@uqtr.ca

Abstract:

Several studies have revealed either self-reported chemosensory alterations in large groups or objective quantified chemosensory impairments in smaller populations of patients diagnosed with COVID-19. However, due to the great variability in published results regarding COVID-19-induced chemosensory impairments and their follow-up, prognosis for chemosensory functions in patients with such complaints remains unclear. Our objective is to describe the various chemosensory alterations associated with COVID-19 and their prevalence and evolution after infection. A cross-sectional study of 704 healthcare workers with a RT-PCR confirmed SARS-CoV-2 infection between 28/2/2020 and 14/6/2020 was conducted 3 to 7 months after onset of symptoms. Data were collected with an online questionnaire. Outcomes included differences in reported chemosensory self-assessment of olfactory, gustatory, and trigeminal functions across time points and Chemosensory Perception Test scores from an easy-to-use at-home self-administered chemosensory test. Among the 704 participants, 593 (84.2%) were women, the mean (SD) age was 42 (12) years, and the questionnaire was answered on average 4.8 (0.8) months after COVID-19. During COVID-19, a decrease in olfactory, gustatory, and trigeminal sensitivities were reported by 81.3%, 81.5% and 48.0% respectively. Three to seven months later, reduced sensitivity was still reported by 52.0%, 41.9% and 23.3% respectively. Chemosensory Perception Test scores indicate that 19.5% of participants had objective olfactory impairment. These data suggest a significant proportion of COVID-19 cases have persistent chemosensory impairments at 3 to 7 months after their infection but the majority of those who had completely lost their olfactory, gustatory, and trigeminal sensitivity have improved.

Keywords: COVID-19, anosmia, parosmia, long-term, taste, trigeminal system

Introduction:

Coronavirus disease-2019 (COVID-19) is an ongoing major public health challenge. Olfactory dysfunction (OD) is a specific symptom that may affect approximately 60% of patients suffering from COVID-19[1-3], and is now considered as a stronger indicator of COVID-19 than fever, cough and shortness of breath[4].

Investigation of the long-term effects of COVID-19 on chemosensory function is hindered by the recent onset of the pandemic and other challenges: First, many studies include a relatively small number of participants[5, 6] or participants with severe forms of COVID-19[7, 8]. Secondly, many studies include participants with an unclear diagnosis of COVID-19, and/or self-diagnosis [9, 10]. Lastly, while individuals with anosmia can usually evaluate their olfactory function with accuracy[11], this self-assessment is often challenging for individuals with intermediate forms of OD (e.g., hyposmia)[12].

OD can be quantitative or qualitative. Quantitative OD defines a reduction of olfactory sensitivity which can be either a complete (*anosmia*) or a partial (*hyposmia*) loss of olfactory function[13]. Qualitative OD describes an altered perception of olfactory stimuli, such as *parosmia*, the perception of qualitatively altered smells, or *phantosmia*, the perception of a smell in the absence of an objective odorant[13, 14]. Overall, the prevalence of OD in the general population is around 20% [15, 16], and all different forms of OD are associated with reduced quality of life and increased risk of depression and anxiety[17]. In addition to OD, COVID-19 also appears to affect other chemosensory functions, i.e. gustatory and trigeminal perception [9, 18].

To comprehensively understand long-term olfactory, gustatory, and trigeminal alterations after COVID-19, we analyzed questionnaire responses from a cohort of healthcare workers infected with SARS-CoV-2 during the first wave of the pandemic (February - June 2020). We

65   also developed a Chemosensory Perception Test (CPT), a formal test employing common

66   household odorants and tastants, to enable accessible yet accurate self-evaluation of

67   chemosensory functions.

Materials and Methods:

Participants

Participants were recruited from a Quebec healthcare worker cohort who have had SARS-CoV-2 infection between 28/2/2020 and 14/6/2020. They were part of a study from the Institut National de Santé Publique du Québec and had agreed to be contacted for other research projects[19]. Inclusion criteria were (1) RT-PCR confirmed COVID-19 (2) above 18 years of age, (3) French or English speakers, (4) completed the online questionnaire, and (5) did not report of other respiratory diseases (bacterial or viral infection, or/and allergies with rhinorrhea) within 2 weeks prior to questionnaire completion or chronic sinusitis (Figure 1).

This study was reviewed and approved by the research ethics board of the CHU de Québec – Université Laval (MP-20-2021-5228) and all protocols were reviewed by an independent Scientific Review Committee. This study also complies with the Declaration of Helsinki for Medical Research Involving Human Subjects. All participants provided an online informed consent prior to participation. The study received funding from the Fonds de recherche du Québec-Santé. No compensation or incentive was offered for participation. Data were collected from August 11 to October 29, 2020. Up to four attempts were made to reach by email potential participants. At the time of data collection, participants were 3-7 months after the onset of COVID-19 symptoms.

Online questionnaire:

All participants were asked to complete an online questionnaire which was adapted from the core questionnaire of the Global Consortium on Chemosensory Research[9].

Demographic information: In the first part of the questionnaire, demographic information

was collected from all participants. Participants were then instructed to provide medical history

and indicate the presence of specific COVID-19 symptoms (Figure 2).

Chemosensory self-assessment: Participants were asked to self-evaluate and report their

olfactory, gustatory, and trigeminal sensitivity using a 10-point visual analog scale (VAS; Figure

2) for three timepoints: (1) before SARS-CoV-2 infection, (2) during SARS-CoV-2 infection and

(3) at questionnaire completion. Further, information on the presence of parosmia or phantosmia

following the infection[20] and alterations in the 5 tastes (sweet, salty, sour, bitter, umami) was

collected.

Chemosensory Perception Test (CPT): Items commonly found in North American

households were used to assess participants' olfactory and gustatory functions, as odor intensity

is the best single predictor to classify individuals with normosmia[21]. Participants had to smell

three substances (peanut butter, jam/jelly, and coffee) and rate odor intensity on a 10-point VAS

(0: no smell at all; 10: very strong smell). We obtained olfactory scores by averaging these

ratings. Pilot data on a total of 93 participants show these scores to accurately detect OD when

compared to the Sniffin' Sticks (cut-off score: 6/10; sensitivity: 0.765; specificity: 0.895;

Supplement 3). Participants were asked to prepare saline and sweet water by dissolving

respectively a teaspoon of salt or 3 teaspoons of sugar in a cup (250 mL) of lukewarm water.

Then, they were asked to taste saline and sweet water and to rate taste intensities on a 10-point

VAS. We obtained gustatory scores by averaging these ratings.

Statistical Analyses:

A Python script (Python 3.7.5, Python Software Foundation, https://www.python.org) was used

to process raw questionnaire data and to calculate the number of participants reporting COVID-

19 symptoms, chronic conditions and recent respiratory illnesses. Processed data were analyzed

and visualized with SPSS 26.0 (Armonk, NY: IBM Corp), GraphPad Prism 8.3.1 (GraphPad

Prism Software, San Diego, CA) and Raincloud plots[22].

Parametric (ANOVA) or non-parametric (Friedman) tests were chosen depending on

whether normality assumption was fulfilled. To evaluate the effects of COVID-19 on *modality*

(olfactory, gustatory, and trigeminal) and *time* (prior to, during and after COVID-19 infection),

for *gender* (women, men), repeated measures (rm) ANOVA with age as a covariate were

computed. To disentangle interactions, separate rmANOVA were carried out for individual

modalities and timepoints with the same factors. Greenhouse-Geisser corrections were used for

sphericity and Tukey's multiple comparisons test were used for post-hoc comparisons.

Friedman's test was followed by Dunn's post-hoc test to correct for multiple comparisons. To

assess the correlation between self-reported olfactory, gustatory, and trigeminal abilities and

results of the CPT, Pearson correlation coefficient or Spearman's rank correlation coefficient

was used. For all statistical tests, alpha was set at 0.05. All results are expressed as mean (SD)

unless otherwise specified.

Results:

Characteristics of participants:

A total of 704 healthcare workers (593 (84.2%) women, mean age of 42.0 (SD:11.7, range 18 – 70) years were included. The questionnaire was completed on average 4.8 (SD: 0.8, range 3-7) months after symptoms onset. COVID-19 symptoms reported by the 704 participants are listed in Table 1.

Quantitative disorders:

Before COVID-19, average self-reported score was 9.0 (1.6), 9.2 (1.3) and 8.9 (1.9) of 10 for olfaction, gustation and trigeminal function, respectively. Among participants, 0.9%, 0.7% and 1.8% respectively reported an absence of olfaction, gustation and trigeminal function (score 0; Figure 3). During COVID-19, average self-reported score was 2.6 (3.6) for olfaction, 3.4 (3.6) for gustation, and 7.0 (3.0) for trigeminal sensitivity. In the 704 participants, 51.1%, 33.5% and 5.7% reported absence of olfaction, gustation and trigeminal function. At time of questionnaire completion, mean scores were 7.4 (2.5), 8.0 (2.2) and 8.5 (2.2) for olfaction, gustation and trigeminal function respectively and absence of chemical senses was reported respectively by 1.4%, 0.7% and 2.3%.

Compared to the baseline chemosensory functions before COVID-19, 572 (81.3%), 574 (81.5) and 338 (48.0%) reported lower olfactory, gustatory, and trigeminal sensitivity during COVID-19. Olfactory and gustatory dysfunction were present in similar proportions (χ^2(2, N=704) =0.02, P=.891) and were different to trigeminal (olfaction: χ^2(2, N=704) = 174.81 P<.001; gustation: χ^2(2, N=704) = 174.56 P<.001). Three to seven months after the infection,

366 (52.0%), 295 (41.9%), 164 (23.3%) reported lower olfactory, gustatory, and trigeminal

sensitivity compared to before COVID-19 (Table 2). These proportions were significantly

different between all three chemosensory systems (χ^2(2, N=704) = 123.46, *P*<.001).

Overall, there were significant effects of *modality* (F(2,1402)=42.83, *P*<.001, η_p^2=0.058;

olfactory<gustatory<trigeminal; all *P*<.001), *time* (F(2,1402)=118.47, *P*<.001, η_p^2=0.145;

during<after<before; all *P*<.001), and *gender* (F(1,701)=5.52, *P*=0.019, η_p^2=0.008; women<men)

and significant interactions between these factors (*modality*time, modality*time*gender*; all

P<.001) on chemosensory self-evaluation. To disentangle these interactions, we analyzed data

separately per chemosensory modality and time points.

<u>Chemosensory modality</u>: With regards to <u>olfactory</u> function, significant main effects of *time*

(F(2,1402)=165.07, *P*<.001 η_p^2=0.191; during<after<before; all *P*<.001; Figure 3A), *age*

(F(1,701)=4.42, *P*=.012, η_p^2=0.009) and *gender* (F(1,701)=4.42, P=.036, η_p^2=0.006; women <

men) were revealed. In addition, we observed significant interactions of *time*age*

(F(2,1402)=23.39, *P*<.001, η_p^2=0.032) and *time*gender* (F(2, 1402)=21.69 , *P*<0.001, η_p^2=0.030).

With regards to <u>gustatory</u> function, we observed significant main effects of *time*

(F(2,1402)=102.97, *P*<.001, η_p^2=0.128; during<after<before; all *P*<.001; Figure 3B) and *gender*

(F(1, 701)=9.80, *P*=.002, η_p^2=0.014; women<men), but no effect of *age*. We also observed

significant interactions of *time*age* (F(2, 1402))=5.97, *P*=.005, η_p^2=0.008) and *time*gender* (F(2,

1402))=20.02 , *P*<.001, η_p^2=0.028).

With regards to <u>trigeminal</u> function, we observed significant main effects of *time*

(F(2,1402)=3.91, *P*=.020, η_p^2=0.006; during<after<before; all *P*<.001; Figure 3C), and age

((1,701)=5.08, *P*=.025, η_p^2=0.007) but no effect of *gender*. We also identified significant

interactions of *time*age* (F(2, 1402)=4.70, *P*=.016, η_p^2=0.007) and *time*gender* (F(2,

1402)=4.50, *P*=.019, η_p^2=0.006).

<u>Time point</u>: With regards to chemosensory function <u>before</u> infection, we observed a significant

effect of *gender* (F(1,701)=8.52, *P*=.004, η_p^2=0.012; men < women), but not of *modality*, *age* nor

interactions. <u>During</u> COVID-19, we observed a significant effects of *modality* (F(2,

1402)=96.714, *P*<.001, η_p^2=0.121; olfaction<gustation<trigeminal; all *P*<.001), *gender* (F(1,

701)=21.98, *P*<.001, η_p^2=0.030; women<men), and age (F(1, 701)=4.74, *P*=.030, η_p^2=0.007).

Further, we found significant interactions *modality*age* (F(2, 1402)=24.185, *P*<.001, η_p^2=0.033)

and *modality*gender* (F(2, 1402)=6.76, *P*=.002, η_p^2=0.010). Finally, <u>after</u> infection, we observed

a significant effect of *modality* (F(2, 1402)=9.91, *P*<.001, η_p^2=0.014;

olfaction<gustation<trigeminal; all *P*<.015), but not of *gender* or *age*, nor any interaction.

Compared to baseline (before infection), changes in chemosensory function were

correlated for all modalities during infection (olfaction-gustation: ρ=0.69; gustation-trigeminal:

ρ=0.43; olfaction-trigeminal: ρ=0.33; all *P*<.001, Figure 4 A-C) and after infection (olfaction-

gustation: ρ=0.69; gustation-trigeminal: ρ=0.40; olfaction-trigeminal: ρ=0.36; all *P*<.001, Figure

4 D-F).

Qualitative disorders:

Among included participants, 78 (11.1%) reported parosmia, 73 (10.4%) experienced

phantosmia and/or 82 (11.6%) had waxing and waning of olfaction following infection. In

addition, 42 (6.0%) claimed that they experienced other forms of OD (hyposmia to specific

substances, hyperosmia, parosmia only at high concentrations or slow identification times).

Furthermore, 335 (47.6%) participants reported changes to perception of sweet, 338 (48.0%)

salty, 293 (41.6%) sour, 309 (43.9%) bitter and 281 (39.9%) umami. A total of 275 (39.1%)

participants reported alterations in all 5 tastes.

Chemosensory Perception Test:

Among the 704 participants, 137 (19.5%) had a CPT score suggestive of OD. Mean CPT scores

were lower for olfaction than gustation (7.84 (1.78) vs 8.42 (2.31); $Z=8.193$, $P<.001$). Neither

age nor *gender* had an effect on CPT scores. CPT scores correlated with self-reported

chemosensory abilities at testing time (olfaction: $\rho=0.67$; gustation: $\rho=0.51$; $P<.001$ for both).

Discussion:

This study reports chemosensory dysfunction 3 to 7 months following SARS-CoV-2 infection in a large cohort of RT-PCR-confirmed healthcare workers. In addition to confirming the now well-established detrimental effect of acute COVID-19 on all three chemosensory systems (olfactory, gustatory, trigeminal), our major findings are: (1) the detrimental effect of COVID-19 lasts beyond the acute phase after the infection, half of those affected indicated that olfactory function had not returned to the baseline levels 3 to 7 months later, while 20% of infected participants reported scores in a formal test that are consistent with the presentation of hyposmia/anosmia; (2) approximately 10% of the patients exhibit parosmia and/or phantosmia; (3) women are more heavily affected than men.

We observed chemosensory dysfunction in the acute phase of COVID-19, which was most pronounced for olfactory function, but less so for gustatory function and even less for trigeminal function. The proportion of participants describing OD and GD in the acute phase of COVID-19 in this study was comparable to earlier studies[23]. Nevertheless, on average 4.8 months after infection and thus well after the acute phase, approximately 50% and 40% of patients reported persistent alterations in olfactory and gustatory sensitivity, respectively; these numbers are higher than what has been reported[24, 25].

We found a moderate-to-strong correlation between self-reported olfactory and gustatory changes, which were stronger than with self-reported trigeminal changes. This could be due to similar pathophysiological alterations in the olfactory and gustatory systems and their differences from that of the trigeminal system. Knowing that the general population often mixes up retro-olfaction (perceiving odors from the substances in the mouth traveling posteriorly and rostrally to the olfactory epithelium) with taste, an alternative explanation would be a misunderstanding of

this nuance by participants despite the fact that specific definitions for each modality were

given[26][27]. The latter hypothesis is more probable since the correlation between gustatory self-

report and CPT gustatory scores using strict gustatory stimuli (salt, sugar) is lower than the

correlation between olfactory self-report and CPT olfactory scores.

Moreover, approximately 10% reported parosmia and/or phantosmia following SARS-

CoV-2 infection. These qualitative smell disorders usually involve unpleasant olfactory

sensations (rotten eggs, sewage, smoke). While the exact patho-mechanism of parosmia and

phantosmia are still to be elucidated, parosmia is probably linked to altered peripheral

input/central processing of olfactory stimuli[28]. Importantly, patients with postviral OD and

parosmia exhibit better recovery rates following olfactory training than those without parosmia[29].

Follow-ups will determine to what extent parosmia predicts a better outcome.

Women's chemical senses were more affected than men by the infection. Women

typically have better scores in olfactory testing than men [30]. In turn, women exhibit a higher

prevalence and a longer persistence of postviral OD[31, 32], in line with our results. Gender

differences could be explained by a multitude of neuroendocrine, social, and cognitive factors[31].

This suggests that the burden of COVID-19-related OD is more important for women than for

men.

Different theories have been proposed to explain the persistence of OD in certain

individuals, ranging from olfactory epithelium dysfunction to central nervous system infection [33-

35]. Since cells of the olfactory epithelium possess the ability to regenerate, the re-establishment

of olfactory function is possible in the context of postinfectious OD [36], as well as in COVID-19-

related OD, where 75-85% of the affected individuals recovered olfactory function within 60

days [24, 37]. In addition to OD and GD, TD has also been reported in patients with COVID-19 [9, 18].

Our study indicates chemosensory dysfunction in 18.9% of participants as measured by the CPT

3 to 7 months after infection.

Persistent chemosensory dysfunctions may be a sign of chronic central nervous system

alterations[38, 39], and there is now evidence that SARS-CoV-2 can infect olfactory sensory

neurons in humans[40]. Other viruses, such as the Japanese encephalitis virus, Varicella-Zoster

virus, measles virus, human immunodeficiency virus and CoVs, were shown to invade the

CNS[41]. Febrile seizures, loss of consciousness, convulsions, ataxia, status epilepticus,

encephalitis, myelitis, neuritis and extrapyramidal symptoms are among extra-pulmonary

symptoms that have been described[42]. The persistence of postinfectious neurological symptoms

may contribute to the development or aggravation of chronic neurological diseases such as

Parkinson, multiple sclerosis, or psychiatric outcomes[41, 43-51]. These patients should be followed

up to document the development of neurological sequalae.

Olfactory and other chemosensory dysfunctions may have detrimental effects. First,

affected individuals can expose themselves to harmful substances such as smoke, gas or spoiled

food[52, 53]. It may trigger dysfunctional nutritional patterns like increased salt and sugar

consumption and anorexia[54, 55]. Individuals with OD also have higher rates of anxiety and

depression[17, 56]. Moreover, a functioning olfactory system may be a necessity in some

workplaces such as in healthcare, where staff are required to have the ability to detect and

qualify the smell of urine, excrement, infected wounds or abnormal smells of breath[57]. Currently,

there is no approved therapy for COVID-19-induced OD, although olfactory training has a

significant effect on olfactory function according to studies on other viral infections[58-60]. Most

importantly, long-term follow-up of these patients will be necessary to assess other signs of

neurological damage.

<u>Limitations</u>

Given the cross-sectional design of the study, a recall bias is possible for all self-reported peri-SARS-CoV-2 infection values before or during the SARS-CoV-2 infection due to the 3-to-7-month gap. This study did not control for potential confounding factors like race and level of education. Finally, the CPT requires further validation for its gustatory and trigeminal components, and it relies on substances found in participants' homes, which may lead to variation in test results due to the differences in the brand, quality, or expiration date of substances and consequently, their ability to trigger equal sensorineural responses.

<u>Conclusions:</u>

Nearly two thirds of SARS-CoV-2 infected patients had chemosensory impairments during their

infection and despite improvements, impairments persist in more than half of them 3 to 7 months

after COVID-19. Quantitative and qualitative olfactory dysfunction as well as persisting

gustatory and trigeminal deficits were common in the cohort presented in this study. Given the

frequency of these problems and the possible neurological underpinnings of these observations,

it will be critical to understand the underlying mechanisms of these chemosensory dysfunctions,

their evolution, and possible therapeutic options.

<u>Acknowledgments:</u>

We thank Josiane Rivard for preparing the online questionnaire, Cécilia Tremblay, Émilie

Aubry-Lafontaine and Frédérique Roy-Côté for data collection and the validation of the

Chemosensory Perception Test, and all study participants and frontline healthcare workers facing

the COVID-19 pandemic. This work was supported by Fonds de recherche du Québec – Santé

(chercheur boursier junior 2 #283144 to JF). NB and JF had full access to all the data in the study

and take responsibility for the integrity of the data and the accuracy of the data analysis. FGL is

the recipient of a tier-2 Canada research Chair. All authors declare no conflict of interest.

References:

1.   Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or
Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. *JAMA*. 2020;323 (20):2089-
2090. doi:10.1001/jama.2020.6771 %J JAMA
2.   Whitcroft KL, Hummel T. Olfactory Dysfunction in COVID-19: Diagnosis and Management.
JAMA. 2020;323 (24):2512-2514. doi:10.1001/jama.2020.8391 %J JAMA
3.   von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-
19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. *ACS Chem*
Neurosci. Oct 7 2020;11(19):2944-2961. doi:10.1021/acschemneuro.0c00460
4.   Gerkin R, Ohla K, Veldhuizen M, Joseph P, Kelly C, Bakke A, et al. Recent Smell Loss Is the
Best Predictor of COVID-19 Among Individuals With Recent Respiratory Symptoms. *Chemical Senses*.
02/01 2021;46
5.   Le Bon S-D, Pisarski N, Verbeke J, Prunier L, Cavelier G, Thill M-P, et al. Psychophysical
evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort
study on 72 patients. *Eur Arch Otorhinolaryngol*. 2020;doi:10.1007/s00405-020-06267-2
6.   Hintschich CA, Wenzel JJ, Hummel T, Hankir MK, Kühnel T, Vielsmeier V, et al.
Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients.
International forum of allergy & rhinology. 2020;10(9):1105-1107. doi:10.1002/alr.22655
7.   Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell
dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. 2020;doi:10.1002/alr.22587
8.   Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory
Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated
Characteristics. *Otolaryngol Head Neck Surg*. 2020;doi:10.1177/0194599820929185
9.   Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More than smell.
COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. *medRxiv*.
2020:2020.05.04.20090902. doi:10.1101/2020.05.04.20090902
10.   Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia
during the COVID-19 pandemic – an observational cohort study. *Journal of Otolaryngology - Head &*
Neck Surgery. 2020/05/04 2020;49(1):26. doi:10.1186/s40463-020-00423-8
11.   Lötsch J, Hummel T. Clinical Usefulness of Self-Rated Olfactory Performance-A Data Science-
Based Assessment of 6000 Patients. *Chem Senses*. Jul 17 2019;44(6):357-364.
doi:10.1093/chemse/bjz029
12.   Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory
function. *Chem Senses*. Oct 2003;28(8):691-4. doi:10.1093/chemse/bjg061
13.   Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al. Position paper
on olfactory dysfunction. *Rhinology*. Jan 31 2016;56(1):1-30. doi:10.4193/Rhin16.248
14.   Sjölund S, Larsson M, Olofsson JK, Seubert J, Laukka EJ. Phantom Smells: Prevalence and
Correlates in a Population-Based Sample of Older Adults. *Chemical senses*. 2017;42(4):309-318.
doi:10.1093/chemse/bjx006
15.   Yang J, Pinto JM. The Epidemiology of Olfactory Disorders. *Curr Otorhinolaryngol Rep*.
2016;4(2):130-141. doi:10.1007/s40136-016-0120-6
16.   Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction.
Laryngoscope. Oct 2004;114 (10):1764-9. doi:10.1097/00005537-200410000-00017
17.   Croy I, Nordin S, Hummel T. Olfactory Disorders and Quality of Life—An Updated Review.
Chemical Senses. 2014;39(3):185-194. doi:10.1093/chemse/bjt072
18.   Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. COVID-19
and the Chemical Senses: Supporting Players Take Center Stage. *Neuron*. 2020;107 (2):219-233.
doi:10.1016/j.neuron.2020.06.032
19.   Carazo SLD, Villeneuve J, Martin R, Deshaies P, Denis G, , Adib G, Tissot F, Dionne M,
De Serres G Characterization and evolution of infection control practices among SARS-CoV-2 infected

healthcare workers of acute care hospitals and long-term care facilities in Quebec, Canada, Spring 2020.
Infect Contr Hospit Epidemiol. in press 2021;
20. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of structured
questions in parosmia assessment. *Laryngoscope*. Aug 2010;120 (8):1707-13. doi:10.1002/lary.20955
21. Parma V, Hannum ME, O'Leary M, Pellegrino R, Rawson NE, Reed DR, et al. SCENTinel 1.0:
development of a rapid test to screen for smell loss. *Chem Senses*. Mar 27
2021;doi:10.1093/chemse/bjab012
22. Allen M, Poggiali D, Whitaker K, Marshall T, van Langen J, Kievit R. Raincloud plots: a multi-
platform tool for robust data visualization [version 2; peer review: 2 approved]. *Wellcome Open*
Research. 2021;4(63)doi:10.12688/wellcomeopenres.15191.2
23. Hajikhani B, Calcagno T, Nasiri MJ, Jamshidi P, Dadashi M, Goudarzi M, et al. Olfactory and
gustatory dysfunction in COVID-19 patients: A meta-analysis study. *Physiol Rep*. Sep 2020;8(18):
e14578. doi:10.14814/phy2.14578
24. Lechien JR, Chiesa-Estomba CM, Beckers E, Mustin V, Ducarme M, Journe F, et al. Prevalence
and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients.
https://doi.org/10.1111/joim.13209. *Journal of Internal Medicine*. 2021/01/05 2021;n/a (n/a)
doi:https://doi.org/10.1111/joim.13209
25. Capelli M, Gatti P. Anosmia in the first coronavirus disease 2019 outbreak in Europe: functional
recovery after eight months. *J Laryngol Otol*. 2021:1-5. doi:10.1017/S0022215121000670
26. Landis BN, Frasnelli J, Reden J, Lacroix JS, Hummel T. Differences Between Orthonasal and
Retronasal Olfactory Functions in Patients With Loss of the Sense of Smell. *Archives of Otolaryngology–*
Head & Neck Surgery. 2005;131 (11):977-981. doi:10.1001/archotol.131.11.977 %J Archives of
Otolaryngology–Head & Neck Surgery
27. Malaty J, Malaty IA. Smell and taste disorders in primary care. *Am Fam Physician*. Dec 15
2013;88(12):852-9.
28. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding Parosmia: An
fMRI Study. *ORL J Otorhinolaryngol Relat Spec*. 2019;81(4):185-192. doi:10.1159/000500558
29. Liu DT, Sabha M, Damm M, Philpott C, Oleszkiewicz A, Hähner A, et al. Parosmia is Associated
with Relevant Olfactory Recovery After Olfactory Training. *Laryngoscope*. Mar 2021;131 (3):618-623.
doi:10.1002/lary.29277
30. Wang X, Zhang C, Xia X, Yang Y, Zhou C. Effect of gender on odor identification at different
life stages: a meta-analysis. *Rhinology*. Oct 1 2019;57(5):322-330. doi:10.4193/Rhin19.005
31. Sorokowski P, Karwowski M, Misiak M, Marczak MK, Dziekan M, Hummel T, et al. Sex
Differences in Human Olfaction: A Meta-Analysis. Systematic Review. 2019-February-13 2019;10 (242)
doi:10.3389/fpsyg.2019.00242
32. Liu J, Pinto JM, Yang L, Li L, Sun J, Miao X, et al. Gender difference in Chinese adults with
post-viral olfactory disorder: a hospital-based study. *Acta Otolaryngol*. Sep 2016;136 (9):976-81.
doi:10.3109/00016489.2016.1172729
33. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of
an Olfactory Route to Brain Infection. *Neuroscientist*. 2020;doi:10.1177/1073858420956905
34. Solomon T. Neurological infection with SARS-CoV-2 — the story so far. *Nature Reviews*
Neurology. 2021/02/01 2021;17(2):65-66. doi:10.1038/s41582-020-00453-w
35. Bilinska K, Butowt R. Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular
Mechanism. *ACS Chem Neurosci*. 2020;doi:10.1021/acschemneuro.0c00406
36. Cavazzana A, Larsson M, Münch M, Hähner A, Hummel T. Postinfectious olfactory loss: A
retrospective study on 791 patients. *Laryngoscope*. Jan 2018;128 (1):10-15. doi:10.1002/lary.26606
37. Mullol J, Alobid I, Mariño-Sánchez F, Izquierdo-Domínguez A, Marin C, Klimek L, et al. The
Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries. *Curr Allergy Asthma*
Rep. 2020;20(10):61-61. doi:10.1007/s11882-020-00961-1

38.	Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain, Behavior, and Immunity*. 2020/03/30/ 2020;doi:https://doi.org/10.1016/j.bbi.2020.03.031

39.	Gori A, Leone F, Loffredo L, Cinicola BL, Brindisi G, De Castro G, et al. COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention. *Front Neurol*. 2020;11:956-956. doi:10.3389/fneur.2020.00956

40.	Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci*. Nov 30 2020;doi:10.1038/s41593-020-00758-5

41.	Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. *Cell Host Microbe*. Apr 17 2013;13(4):379-93. doi:10.1016/j.chom.2013.03.010

42.	Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. *Front Cell Neurosci*. 2018;12:386. doi:10.3389/fncel.2018.00386

43.	Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. *J Virol*. Oct 2000;74(19):8913-21. doi:10.1128/jvi.74.19.8913-8921.2000

44.	Cohen ME, Eichel R, Steiner-Birmanns B, Janah A, Ioshpa M, Bar-Shalom R, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. *Lancet Neurol*. Oct 2020;19(10):804-805. doi:10.1016/s1474-4422 (20)30305-7

45.	Cristallo A, Gambaro F, Biamonti G, Ferrante P, Battaglia M, Cereda PM. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. *New Microbiol*. Apr 1997;20(2):105-14.

46.	Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. *Mov Disord*. 1992;7(2):153-8. doi:10.1002/mds.870070210

47.	Johnson-Lussenburg CM, Zheng Q. Coronavirus and multiple sclerosis: results of a case/control longitudinal serological study. *Adv Exp Med Biol*. 1987;218:421-9. doi:10.1007/978-1-4684-1280-2_51

48.	Morris JA. Clinical viral infections and multiple sclerosis. *Lancet*. Aug 3 1985;2 (8449):273. doi:10.1016/s0140-6736(85)90318-6

49.	Murray RS, Brown B, Brian D, Cabirac GF. Detection of coronavirus RNA and antigen in multiple sclerosis brain. *Ann Neurol*. May 1992;31(5):525-33. doi:10.1002/ana.410310511

50.	Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple sclerosis patients. *Virology*. Nov 1992;191 (1):502-5. doi:10.1016/0042-6822 (92)90220-j

51.	Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. Apr 1 2021;doi:10.1016/s2215-0366 (21)00084-5

52.	Schiffman SS. Smell and Taste. In: Birren JE, ed. *Encyclopedia of Gerontology (Second Edition)*. Elsevier; 2007:515-525.

53.	Gonzales GM, Cook MJ. CHAPTER 13 - DISORDERS OF SMELL AND TASTE. In: Schapira AHV, Byrne E, DiMauro S, et al, eds. *Neurology and Clinical Neuroscience*. Mosby; 2007:171-177.

54.	Aschenbrenner K, Hummel C, Teszmer K, Krone F, Ishimaru T, Seo HS, et al. The influence of olfactory loss on dietary behaviors. *Laryngoscope*. Jan 2008;118 (1):135-44. doi:10.1097/MLG.0b013e318155a4b9

55.	Mattes R, Cowart B, Schiavo M, Arnold C, Garrison B, Kare M, et al. Dietary evaluation of patients with smell and/or taste disorders. *The American journal of clinical nutrition*. 03/01 1990;51:233-40. doi:10.1093/ajcn/51.2.233

56.	Kohli P, Soler ZM, Nguyen SA, Muus JS, Schlosser RJ. The Association Between Olfaction and Depression: A Systematic Review. *Chem Senses*. Jul 2016;41(6):479-86. doi:10.1093/chemse/bjw061

57.	Kelly M. Scent of a patient: an underestimated role in clinical practice? *Br J Gen Pract*. 2012;62 (600):378-378. doi:10.3399/bjgp12X652481

58.	Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a meta-analysis. *Rhinology*. Mar 1 2017;55(1):17-26. doi:10.4193/Rhin16.195

59.   Doty RL. Treatments for smell and taste disorders: A critical review. *Handb Clin Neurol*.
2019;164:455-479. doi:10.1016/b978-0-444-63855-7.00025-3
60.   Damm M, Pikart LK, Reimann H, Burkert S, Göktas Ö, Haxel B, et al. Olfactory training is
helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. *Laryngoscope*. Apr
2014;124 (4):826-31. doi:10.1002/lary.24340
61.   Rumeau C, Nguyen DT, Jankowski R. How to assess olfactory performance with the Sniffin'
Sticks test®. *European Annals of Otorhinolaryngology, Head and Neck Diseases*. 2016/06/01/ 2016;133
(3):203-206. doi:https://doi.org/10.1016/j.anorl.2015.08.004
62.   Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell
Identification Test: a standardized microencapsulated test of olfactory function. *Physiol Behav*. Mar
1984;32(3):489-502. doi:10.1016/0031-9384 (84)90269-5

Table 1. COVID-19 symptoms of the 704 participants.

Symptoms at time of SARS-CoV-2 infection	No. (%)
Fever	353 (50.1%)
Dry cough	361 (51.7%)
Cough with mucus	77 (10.9%)
Dyspnea	316 (44.9%)
Chest tightness	201 (28.6%)
Runny nose	226 (32.1%)
Sore throat	330 (46.9%)
Changes in food flavor	471 (66.9%)
Changes in smell	520 (73.9%)
Loss of appetite	323 (45.9%)
Headache	518 (73.6%)
Muscle aches	444 (63.1%)
Fatigue	611 (86.8%)
Diarrhea	259 (36.8%)
Abdominal pain	102 (14.5%)
Nausea	179 (25.4%)

466 **Table 2.** Self-reported chemosensory alterations by age group and gender during and 3 to 7

467 months following COVID-19 (n=704).

		During acute COVID-19			3-7 months after COVID-19		
		Olfaction	Gustation	Trigeminal	Olfaction	Gustation	Trigeminal
Age	Gender	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
18-29	M (N= 11)	9 (81.8)	9 (81.8)	4 (36.4)	6 (54.5)	5 (45.5)	3 (27.3)
	F (N=115)	106 (92.2)	106 (92.2)	54 (47.0)	68 (59.1)	55 (47.8)	16 (13.9)
30-39	M (N=26)	23 (88.5)	21 (80.8)	12 (46.2)	13 (50.0)	7 (26.9)	4 (15.4)
	F (N=153)	133 (86.9)	129 (84.3)	77 (50.3)	83 (54.2)	63 (41.2)	37 (24.2)
40-49	M (N=33)	23 (69.7)	23 (69.7)	13 (39.4)	12 (36.4)	9 (27.3)	5 (15.2)
	F (N=165)	142 (85.5)	137 (83.0)	83 (50.3)	97 (58.8)	77 (46.7)	42 (25.5)
50-59	M (N=28)	13 (46.4)	14 (50.0)	9 (32.1)	7 (25.0)	7 (25.0)	4 (14.3)
	F (N=128)	100 (78.1)	102 (79.7)	66 (51.6)	62 (48.4)	57 (44.5)	39 (30.5)
60+	M (N=13)	5 (38.5)	6 (46.2)	5 (38.5)	2 (15.4)	1 (7.7)	3 (23.1)
	F (N=32)	19 (59.4)	27 (84.4)	15 (46.9)	16 (50.0)	14 (43.8)	11 (34.4
Total (N=704)		**572 (81.3)**	**574 (81.5)**	**338 (48.0)**	**366 (52.0)**	**295 (41.9)**	**164 (23.2)**

470 **Figure 1. Flowchart of participant inclusion/exclusion procedures.** Flowchart of the study

471 design. INSPQ: Institut national de santé publique.

472   **Figure 2. Web-based interface and structure of the online questionnaire**. Left, Self-rating of

473   olfaction and reporting of CPT using VAS through the web-based interface, as viewed by the

474   participant. Right, Sections of the online questionnaire. VAS: visual analog scale.

Consent		
Q1-Q4: personal information		• Year of birth • Place of residence • Gender
Q5-Q10: COVID-related questions		• Diagnosis of COVID-19 • Date of symptom onset • Date of positive COVID-19 test • Stage of COVID-19 • COVID-19 related symptoms • Treatment/medication received
Q11-Q20: medical history and substance use		• Other respiratory diseases in last two weeks • Symptoms associated with respiratory diseases • Treatment received • Usage of cigarette, e-cigarette, marijuana/cannabis • History of other diseases
Q21-Q31: self-reported OD, GD and TD scores		• Self-evaluation of olfactory, gustatory and trigeminal functions • Change in olfaction and gustation
Q32-Q61: Chemosensory Perception Test		• Availability of substances at home • Reporting of smell and/or taste of the substance

Figure 3. Self-reported scores for the chemosensory modalities before, during and after

COVID-19 infection (n=704). Raincloud plot representing self-reported scores for olfaction,

gustation, and trigeminal function before, during and after COVID-19. Ratings from individual

participants are displayed as dots. Boxplots show the first to third quartiles, horizontal line denotes

the median, and whiskers denote 1.5 times interquartile range. Compared to baseline, self-reported

scores of olfaction, gustation and trigeminal function were significantly lower during COVID-19

and have not fully returned to baseline values 5 months after COVID-19.

Figure 4. Correlations between alterations in chemosensory modalities (n=704). Red squares,

correlations between alterations in olfaction, gustation, and trigeminal functions during COVID-

19. Grey hexagons, correlations between alterations in olfaction, gustation, and trigeminal

functions after COVID-19. Darker colors indicate higher occurrence.

486
487

 Supplementary 1:

Validation of the Chemosensory Perception Test

This study was reviewed and approved by the research ethics board of the Université du Quebec à

Trois-Rivières (CER-20-268-08-01.04). All participants provided a verbal or written informed

consent prior to participation.

Experiment 1:

Methods

Participants were recruited among previously tested groups. Olfactory testing was performed

using the standardized Sniffin' Sticks test at our laboratory from 2016 to 2019. Exclusion criteria

was any perceived changes of their sense of smell since previous testing. Participants were

distributed into 2 groups based on their Threshold-Discrimination-Identification (TDI) scores.

The first group consists of participants with normal olfactory function (normosmia), defined as

TDI scores above 30.5[61]. The second group had subjective olfactory dysfunction and equivalent

TDI scores. Participants were administered CPT by means of a telephone interview.

Results:

TDI scores in the first group range from 32.5 to 41.5 (N= 19, 9 women and 10 men, age range [60-

78]). TDI scores in the second group ranged from 8 to 30.25 (N= 17, 7 women and 10 men, age

range [57-77]). CPT scores were positively correlated with the Sniffin' Sticks (ρ=0.837, P<0.001).

A cut-off score of 6 at the CPT had a sensitivity of 0.765 and specificity of 0.895.

Experiment 2:

Methods:

Participants were recruited among previously tested groups, participants from this cross-sectional

study and in the public via social media. They were administered the University of Pennsylvania

Smell Identification Test (UPSIT) (which was sent by mail) and the CPT under direct supervision

through videoconferencing. Participants were distributed into 2 groups based on their UPSIT

scores with a score equal or less than 33 in males and 34 in females defining hyposmia[62].

Results:

UPSIT scores in the normosmic group ranged from 34 to 28 (n=29 (21 women), age range [22-

73]). The hyposmic group had UPSIT scores ranging from 9 to 34 (n= 28 (21 women), age range:

[22-72]). CPT scores were significantly correlated with the UPSIT score ($\rho=0.377$, $P=0.004$) in

the whole group of participants. We found this correlation to be much stronger in the hyposmic

group ($\rho=0.702$, $P<0.001$).

Conclusions:

The CPT allows for distinction between normosmia and olfactory dysfunction with high sensitivity

and specificity. CPT scores are significantly correlated to UPSIT and Sniffin Sticks scores,

especially in a group of individuals with olfactory dysfunction.

525
526